en.wikipedia.org/wiki/Buspirone

The article states that "Metabolic acidosis, as in diabetes" is a contraindication for buspirone. That does not match current authoritative drug labeling.

• The current U.S. FDA-approved prescribing information on DailyMed lists buspirone’s contraindications as hypersensitivity to buspirone hydrochloride and use with/around MAOIs because of serotonin syndrome and/or elevated blood pressure risk.
• The same labeling does not list metabolic acidosis or diabetes as a contraindication.
• NCBI’s StatPearls review, which summarizes FDA product labeling and standard clinical references, likewise lists buspirone contraindications as prior hypersensitivity and MAOI-related situations, again not metabolic acidosis.

Because contraindications are explicitly enumerated in prescribing information, adding "metabolic acidosis, as in diabetes" is factually incorrect and likely a mix-up with contraindications for other medications (for example, some antidiabetic drugs), not buspirone.

The wording "but was not patented until 1980" is misleadingly late.

Two patent records show that buspirone was already covered before 1980:

1. U.S. Patent 3,717,634 (assigned to Mead Johnson) was filed on November 24, 1969 and published on February 20, 1973. Google Patents identifies buspirone directly in the patent record for this earlier patent.
2. The later GB2089341A / Buspirone Process patent has a 1980-12-11 priority date, but its own description explicitly says it is a new process for the preparation of buspirone and that prior art U.S. Patent No. 3,717,634 disclose[s] synthesis of the relevant compounds. In other words, the 1980-era patent was not the first patenting of buspirone; it was a later process patent.

So the article’s wording is incorrect as written: buspirone-related patent protection existed before 1980, and the 1980 date refers to a later process patent rather than the first patenting of buspirone.